Combined Tumor Infiltrating Lymphocytes and PD-L1 Status in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

IF 2.2 3区医学 Q1 OTORHINOLARYNGOLOGY Head and Neck-Journal for the Sciences and Specialties of the Head and Neck Pub Date : 2025-03-05 DOI:10.1002/hed.28128

Catherine T. Haring, Joshua D. Smith, Sarah M. Dermody, Jonathan B. McHugh, William R. Perry, Collin Brummel, Matthew E. Spector, J. Chad Brenner, Paul L. Swiecicki

{"title":"Combined Tumor Infiltrating Lymphocytes and PD-L1 Status in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","authors":"Catherine T. Haring, Joshua D. Smith, Sarah M. Dermody, Jonathan B. McHugh, William R. Perry, Collin Brummel, Matthew E. Spector, J. Chad Brenner, Paul L. Swiecicki","doi":"10.1002/hed.28128","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To determine if the assessment of CD8+ tumor-infiltrating lymphocytes (TILs) adds prognostic information to the PD-L1 combined positive score (CPS) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective case series was performed of 77 patients with R/M HNSCC between 2003 and 2019. From pre-treatment biopsies, CD8+ TILs and PD-L1 CPS were quantified on a tissue microarray. Associations of biomarkers with overall survival and immune checkpoint inhibition (ICI) response were assessed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Neither CD8+ TIL counts nor PD-L1 CPS alone were associated with overall survival; however, combined high TILs and CPS ≥ 1 were associated with improved survival compared to low TILS and CPS < 1 (18.5 vs. 10.0 months, <i>p</i> = 0.058). For patients treated with ICI (<i>n</i> = 28), PD-L1 CPS predicted ICI response more strongly than CD8+ TILs.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In R/M HNSCC, the combination of PD-L1 CPS and CD8+ TILs is a stronger prognostic biomarker for overall survival compared with either biomarker alone.</p>\n </section>\n </div>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":"47 8","pages":"2114-2122"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hed.28128","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hed.28128","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

To determine if the assessment of CD8+ tumor-infiltrating lymphocytes (TILs) adds prognostic information to the PD-L1 combined positive score (CPS) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Methods

A retrospective case series was performed of 77 patients with R/M HNSCC between 2003 and 2019. From pre-treatment biopsies, CD8+ TILs and PD-L1 CPS were quantified on a tissue microarray. Associations of biomarkers with overall survival and immune checkpoint inhibition (ICI) response were assessed.

Results

Neither CD8+ TIL counts nor PD-L1 CPS alone were associated with overall survival; however, combined high TILs and CPS ≥ 1 were associated with improved survival compared to low TILS and CPS < 1 (18.5 vs. 10.0 months, p = 0.058). For patients treated with ICI (n = 28), PD-L1 CPS predicted ICI response more strongly than CD8+ TILs.

Conclusions

In R/M HNSCC, the combination of PD-L1 CPS and CD8+ TILs is a stronger prognostic biomarker for overall survival compared with either biomarker alone.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肿瘤浸润淋巴细胞和PD-L1在复发/转移性头颈部鳞状细胞癌中的联合状态。

目的：确定CD8+肿瘤浸润淋巴细胞（TILs）的评估是否能在复发/转移（R/M）头颈部鳞状细胞癌（HNSCC）的PD-L1联合阳性评分（CPS）中增加预后信息。方法：回顾性分析2003 - 2019年77例R/M型HNSCC患者的病例系列。从治疗前活检，CD8+ TILs和PD-L1 CPS在组织芯片上定量。评估生物标志物与总生存期和免疫检查点抑制（ICI）反应的关系。结果：CD8+ TIL计数和单独的PD-L1 CPS均与总生存期无关；然而，与低TILs和CPS相比，联合高TILs和CPS≥1与生存率提高相关。结论：在R/M HNSCC中，PD-L1 CPS和CD8+ TILs的联合与单独的任何一种生物标志物相比，是总生存率更强的预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 医学-耳鼻喉科学

CiteScore

7.00

自引率

6.90%

发文量

278

审稿时长

1.6 months

期刊介绍： Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.